Molecular Medicine Reports 2021 June [Link] Takeo Tatsuta, Arisu Nakasato, Shigeki Sugawara, Masahiro Hosono Abstract Malignant pleural mesothelioma (MPM) is a universally lethal type of cancer that is increasing in incidence worldwide; therefore, the development of new drugs for MPM is an urgent task. Bullfrog sialic acid‑binding lectin (cSBL) is a multifunctional protein that has…

Read More

Virchows Archiv 2021 April 14 [Link] Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Avérous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Olivier Harou, Françoise Galateau Sallé, Laurent Villeneuve, Olivier Glehen, Sylvie Isaac 8, Juliette Hommell-Fontaine, Frédéric Bibeau Abstract Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship…

Read More

The American Journal of Surgical Pathology 2021 March 29 [Link] Julia R Naso, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract The separation of malignant mesothelioma from non-small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled homolog 2 (DAB2) have recently been proposed as sensitive/specific markers of…

Read More

Journal of Thoracic Disease 2021 February [Link] Camila M Baldavira, Juliana Machado-Rugolo, Tabatha G Prieto, Daniel R Bastos, Marcelo Balancin, Alexandre M Ab’Saber, Lygia B Yaegashi, Paola C Souza, Cecilia Farhat, Teresa Y Takagaki, Maria Ap Nagai, Vera L Capelozzi Abstract Background: Pleckstrin homology domain family A (PHLDA) genes play important roles in cancer cellular…

Read More

Thoracic Cancer 2021 March 4 [Link] Jordi Guzmán-Casta, Sonia Carrasco-CaraChards, Jorge Guzmán-Huesca, Carla Paola Sánchez-Ríos, Rodrigo Riera-Sala, José Fabián Martínez-Herrera, Erika Sagrario Peña-Mirabal, Diana Bonilla-Molina, Jorge Arturo Alatorre-Alexander, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid Abstract Background: Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced…

Read More

Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…

Read More

Oncology Letters 2021 February [Link] Vincenzo Fontana, Maria Pia Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Paolo Dessanti, Silvio Roncella Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting…

Read More

Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…

Read More